PMID- 33981226
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210514
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Hengshun Aromatic Vinegar Improves Glycolipid Metabolism in Type 2 Diabetes 
      Mellitus via Regulating PGC-1alpha/PGC-1beta Pathway.
PG  - 641829
LID - 10.3389/fphar.2021.641829 [doi]
LID - 641829
AB  - Hengshun aromatic vinegar (HSAV), produced by typical solid-state or liquid-state 
      fermentation techniques, is consumed worldwide as a food condiment. HSAV shows 
      multiple bioactivities, but its activity in type 2 diabetes mellitus (T2DM) and 
      possible mechanisms have not been reported. In this study, the effects of HSAV 
      against T2DM were evaluated in insulin-induced HepG2 cells and high-fat diet 
      (HFD) and streptozotocin (STZ) induced T2DM rats. Then, the mechanisms of HSAV 
      against T2DM were explored by Real-time PCR, Western blot, immunofluorescence 
      assays, siRNA transfection and gene overexpression experiments. Results indicated 
      that HSAV significantly improved glucose consumption and reduced triglycerides 
      (TG) contents in metabolic disordered HepG2 cells. Meanwhile, HSAV obviously 
      alleviated general status, liver and kidney functions of T2DM rats, and decreased 
      hyperglycemia and hyperlipidemia, improved insulin resistance, and reduced lipid 
      accumulation in liver. Mechanism studies indicated that HSAV markedly 
      down-regulated the expression of proliferator-activated receptor gamma coactivator-1alpha 
      (PGC-1alpha), then regulated peroxisome proliferators-activated receptor alpha 
      (PPAR-alpha)/protein kinase B (AKT) signal pathway mediated gluconeogenesis and 
      glycogen synthesis. Meanwhile, HSAV significantly up-regulated 
      proliferator-activated receptor gamma coactivator-1beta (PGC-1beta), and subsequently 
      decreased sterol regulatory element binding protein-1c (SREBP-1c) pathway 
      mediated lipogenesis. In conclusion, HSAV showed potent anti-T2DM activity in 
      ameliorating dysfunction of glycolipid metabolism through regulating 
      PGC-1alpha/PGC-1beta pathway, which has a certain application prospect as an effective 
      diet supplement for T2DM therapy in the future.
CI  - Copyright (c) 2021 Li, Tan, Zhang, Guan, Zhang, Yin, Gao, Zhu and Xu.
FAU - Li, Guoquan
AU  - Li G
AD  - School of Food and Biological Engineering, Jiangsu University, Zhenjiang, China.
AD  - Jiangsu Hengshun Vinegar Industry Co., Ltd., Zhenjiang, China.
FAU - Tan, Xuemei
AU  - Tan X
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
FAU - Zhang, Bao
AU  - Zhang B
AD  - Jiangsu Hengshun Vinegar Industry Co., Ltd., Zhenjiang, China.
FAU - Guan, Linshu
AU  - Guan L
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
FAU - Zhang, Yidan
AU  - Zhang Y
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
FAU - Yin, Lianhong
AU  - Yin L
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
FAU - Gao, Meng
AU  - Gao M
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
FAU - Zhu, Shenghu
AU  - Zhu S
AD  - Jiangsu Hengshun Vinegar Industry Co., Ltd., Zhenjiang, China.
FAU - Xu, Lina
AU  - Xu L
AD  - College of Pharmacy, Dalian Medical University, Dalian, China.
LA  - eng
PT  - Journal Article
DEP - 20210426
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8109051
OTO - NOTNLM
OT  - PGC-1alpha
OT  - PGC-1beta
OT  - aromatic vinegar
OT  - glucolipid metabolism
OT  - gluconeogenesis
OT  - glycogen synthesis
OT  - lipid synthesis
COIS- GL, BZ, and SZ were employed by Jiangsu Hengshun Vinegar Industry Co., Ltd. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/05/14 06:00
MHDA- 2021/05/14 06:01
PMCR- 2021/04/26
CRDT- 2021/05/13 06:24
PHST- 2020/12/15 00:00 [received]
PHST- 2021/04/12 00:00 [accepted]
PHST- 2021/05/13 06:24 [entrez]
PHST- 2021/05/14 06:00 [pubmed]
PHST- 2021/05/14 06:01 [medline]
PHST- 2021/04/26 00:00 [pmc-release]
AID - 641829 [pii]
AID - 10.3389/fphar.2021.641829 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Apr 26;12:641829. doi: 10.3389/fphar.2021.641829. 
      eCollection 2021.